Want to see IN:AUROPHARMA full AI Analyst Report?
Aurobindo Pharma Ltd (AUROPHARMA) Financial Statements
Aurobindo Pharma Ltd Financial Overview
Aurobindo Pharma Ltd's market cap is currently $965.37B. The company's EPS TTM is $64.00; its P/E ratio is 26.27; and it has a dividend yield of 0.24%. Aurobindo Pharma Ltd is scheduled to report earnings on November 4, 2026, and the estimated EPS forecast is $19.37. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 336.53B | $ 317.24B | $ 290.02B | $ 248.55B | $ 234.55B |
| Gross Profit | $ 131.96B | $ 182.40B | $ 160.16B | $ 132.14B | $ 130.06B |
| Operating Income | $ 50.78B | $ 120.01B | $ 104.50B | $ 81.05B | $ 78.06B |
| EBITDA | $ 72.74B | $ 65.78B | $ 58.83B | $ 37.56B | $ 44.33B |
| Net Income | $ 35.05B | $ 34.86B | $ 31.73B | $ 19.27B | $ 26.48B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 106.18B | $ 82.36B | $ 63.25B | $ 62.24B | $ 45.58B |
| Total Assets | $ 585.02B | $ 497.85B | $ 450.72B | $ 398.90B | $ 339.22B |
| Total Debt | $ 80.73B | $ 82.63B | $ 66.48B | $ 52.86B | $ 32.79B |
| Net Debt | $ -17.97B | $ 273.80M | $ 32.54B | $ 8.90B | $ -8.84B |
| Total Liabilities | $ 206.19B | $ 171.38B | $ 152.21B | $ 130.38B | $ 93.48B |
| Stockholders' Equity | $ 378.91B | $ 326.53B | $ 298.43B | $ 268.40B | $ 245.76B |
| Cash Flow | |||||
| Free Cash Flow | $ 28.27B | $ 19.57B | $ -11.27B | $ -3.34B | $ 23.12B |
| Operating Cash Flow | $ 55.13B | $ 39.25B | $ 24.35B | $ 23.87B | $ 50.16B |
| Investing Cash Flow | $ -37.89B | $ -18.76B | $ -42.56B | $ -39.78B | $ -32.12B |
| Financing Cash Flow | $ -9.25B | $ 1.20B | $ 8.00B | $ 18.14B | $ -29.69B |
Currency in INR